How should a pregnant patient with a history of focal segmental glomerulosclerosis and current proteinuria be managed?

Management of Pregnant Patient with History of FSGS and Current Proteinuria

A pregnant patient with previous focal segmental glomerulosclerosis and current proteinuria requires coordinated nephrology-obstetrics care with close monitoring, optimized supportive therapy, and deferral of kidney biopsy until postpartum unless there is rapidly progressive renal failure. 1

Initial Assessment and Diagnostic Approach

The critical first step is distinguishing between three possibilities: preeclampsia, recurrent/active FSGS, or collapsing glomerulopathy triggered by pregnancy.

Key diagnostic considerations:

• Measure sFlt-1/PlGF ratio to exclude preeclampsia, as this biomarker has proven valuable for differentiating primary glomerular disease from preeclampsia 2
• Check serum creatinine trajectory - rapid deterioration (e.g., rising from 1.8 to 5 mg/dL within days) suggests active glomerular disease requiring urgent intervention 3
• Quantify 24-hour proteinuria to establish baseline and monitor progression
• Assess for hematuria with RBC casts, which suggests active glomerulonephritis rather than preeclampsia 3
• Evaluate for secondary causes: HIV, hepatitis, autoimmune diseases 1

A common pitfall: Attributing all proteinuria in pregnancy to preeclampsia. Primary FSGS can present de novo or recur during pregnancy, and collapsing glomerulopathy can develop specifically in the third trimester 4.

Management Strategy

Supportive Care (First-Line for All Patients)

The primary focus should be optimized supportive therapy 1:

• Dietary sodium restriction <2.0 g/day to reduce edema, control blood pressure, and reduce proteinuria 1
• Protein intake 0.8-1 g/kg/day with addition of up to 5 g/day to compensate for urinary losses in nephrotic-range proteinuria 1
• Blood pressure control targeting <120/80 mm Hg (though specific pregnancy targets may differ) 5
• Monitor for thromboembolic complications given nephrotic syndrome risk

Immunosuppression Considerations

The decision to use immunosuppression during pregnancy is complex and depends on disease severity:

• If proteinuria is stable and renal function preserved: Defer immunosuppression until postpartum when kidney biopsy can confirm diagnosis 6
• If rapidly progressive renal failure develops: Consider empirical high-dose corticosteroids (prednisone) as first-line, as this has been used successfully during pregnancy 6, 7
• Tacrolimus can be added if steroids fail, with documented use in pregnancy for FSGS 6
• Rituximab has emerging safety data in pregnancy, with successful outcomes reported in steroid-dependent nephrotic syndrome, though this should be reserved for refractory cases 8

Timing of Delivery

Delivery timing balances maternal kidney function against fetal maturity:

• If proteinuria worsens dramatically (e.g., >23 g/24h) or maternal renal function deteriorates despite treatment, early delivery may be necessary even at 31 weeks 6
• For third-trimester collapsing glomerulopathy associated with preeclampsia, delivery often results in disease resolution without need for immunosuppression 4
• Pregnancy termination may be required in second trimester if rapidly progressive renal failure develops 3

Postpartum Management

Kidney biopsy should be performed 4 weeks to 4 months postpartum to confirm diagnosis if not done during pregnancy 3, 6. This is essential because:

• Preeclampsia should resolve by 4-12 weeks postpartum 5
• Persistent proteinuria or hypertension beyond this timeframe indicates underlying glomerular disease requiring biopsy 5
• Collapsing glomerulopathy may resolve spontaneously after delivery, avoiding unnecessary immunosuppression 4

Follow-up protocol:

• Assess for proteinuria and hypertension at 3-6 months postpartum 5
• Annual medical reviews for at least 5-10 years given increased lifetime risk of CKD and cardiovascular disease 5
• Comprehensive kidney evaluation including ultrasound, serum creatinine, and electrolytes even if proteinuria resolves 5

Special Considerations

Fetal monitoring: Rare cases report transplacental transmission of permeability factors (suPAR) causing fetal echogenic kidneys and oligohydramnios, which may respond to maternal corticosteroid therapy 7. Newborns may have transient proteinuria and renal dysfunction requiring monitoring.

Future pregnancy counseling: Women should be informed about the 15-70% risk of recurrent complications in subsequent pregnancies, with risk increasing after early-onset disease 5. Pre-pregnancy nephrology consultation is essential for risk stratification 1.